Hepatitis C virus p7: Molecular function and importance in hepatitis C virus life cycle and potential antiviral target

Liver International

Volumn 31, Issue 5, 2011, Pages 606-617

  Khaliq, Saba ^a   Jahan, Shah ^a   Hassan, Sajida ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

HCV; Importance in HCV life; Ion channel; P7; Therapy

Indexed keywords

ALPHA2B INTERFERON; AMANTADINE; ANTIVIRUS AGENT; BIT 225; HEMAGGLUTININ; HEXAHISTIDINE; INTERFERON; ION CHANNEL; N[5 (1 METHYL 1H PYRAZOL 4 YL)NAPHTHALENE 2 CARBONYL]GUANIDINE; NONSTRUCTURAL PROTEIN 2; NUCLEOSIDE ANALOG; PROTEIN VP7; RIBAVIRIN; RIMANTADINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA A; LIFE CYCLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS PATHOGENESIS;

ANIMALS; ANTIVIRAL AGENTS; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; HYDROGEN-ION CONCENTRATION; ION CHANNELS; MUTATION; PROTEIN CONFORMATION; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 79953329350     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02442.x     Document Type: Review

References (116)

1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36 (Suppl. 1): S21-9.
2. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 47-52.
3. Fargion S, Fracanzani AL, Valenti L. Treatment choices for people infected with HCV. J Antimicrob Chemother 2004; 53: 708-12.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
5. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group. N Engl J Med 1998; 339: 1485-92.
6. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006; 43 (Suppl. 1): S207-20.
7. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 2004; 85 (Part 11): 3173-88.
8. Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998; 143: 2493-503.
9. Clarke B. Molecular virology of hepatitis C virus. J Gen Virol 1997; 78 (Part 10): 2397-410.
10. Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 2000; 242: 55-84.
11. Xu Z, Choi J, Yen TS, et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J 2001; 20: 3840-8.
12. Egger D, Wolk B, Gosert R, et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002; 76: 5974-84.
13. Schmidt-Mende J, Bieck E, Hugle T, et al. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 2001; 276: 44052-63.
14. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 2005; 102: 17717-22.
15. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85 (Part 9): 2485-502.
16. Carrere-Kremer S, Montpellier-Pala C, Cocquerel L, et al. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol 2002; 76: 3720-30.
17. Lin C, Lindenbach BD, Pragai BM, McCourt DW, Rice CM. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J Virol 1994; 68: 5063-73.
18. Mizushima H, Hijikata M, Tanji Y, Kimura K, Shimotohno K. Analysis of N-terminal processing of hepatitis C virus nonstructural protein 2. J Virol 1994; 68: 2731-4.
19. Selby MJ, Glazer E, Masiarz F, Houghton M. Complex processing and protein:protein interactions in the E2:NS2 region of HCV. Virology 1994; 204: 114-22.
20. Griffin SD, Beales LP, Clarke DS, et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 2003; 535: 34-8.
21. Pavlovic D, Neville DC, Argaud O, et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci USA 2003; 100: 6104-8.
22. Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.
23. Sakai A, Claire MS, Faulk K, et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci USA 2003; 100: 11646-51.
24. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993; 67: 1385-95.
25. Mizushima H, Hijikata M, Asabe S, et al. Two hepatitis C virus glycoprotein E2 products with different C termini. J Virol 1994; 68: 6215-22.
26. Dubuisson J, Hsu HH, Cheung RC, et al. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 1994; 68: 6147-60.
27. Ghibaudo D, Cohen L, Penin F, Martin A. Characterization of GB virus B polyprotein processing reveals the existence of a novel 13-kDa protein with partial homology to hepatitis C virus p7 protein. J Biol Chem 2004; 279: 24965-75.
28. Harada T, Tautz N, Thiel HJ. E2-p7 region of the bovine viral diarrhea virus polyprotein: processing and functional studies. J Virol 2000; 74: 9498-506.
29. Carrere-Kremer S, Montpellier C, Lorenzo L, et al. Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions. J Biol Chem 2004; 279: 41384-92.
30. Ait-Goughoulte M, Hourioux C, Patient R, e al. Core protein cleavage by signal peptide peptidase is required for hepatitis C virus-like particle assembly. J Gen Virol 2006; 87 (Part 4): 855-60.
31. Griffin SD, Harvey R, Clarke DS, et al. A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. J Gen Virol 2004; 85 (Part 2): 451-61.
32. Griffin S, Clarke D, McCormick C, Rowlands D, Harris M. Signal peptide cleavage and internal targeting signals direct the hepatitis C virus p7 protein to distinct intracellular membranes. J Virol 2005; 79: 15525-36.
33. Mottola G, Cardinali G, Ceccacci A, et al. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology 2002; 293: 31-43.
34. aqshenas G, Mackenzie JM, Dong X, Gowans EJ. Hepatitis C virus p7 protein is localized in the endoplasmic reticulum when it is encoded by a replication-competent genome. J Gen Virol 2007; 88 (Part 1): 134-42.
35. Carrasco L. Modification of membrane permeability by animal viruses. Adv Virus Res 1995; 45: 61-112.
36. ldabe R, Carrasco L. Induction of membrane proliferation by poliovirus proteins 2C and 2BC. Biochem Biophys Res Commun 1995; 206: 64-76.
37. Duff KC, Ashley RH. The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. Virology 1992; 190: 485-9.
38. Ewart GD, Sutherland T, Gage PW, Cox GB. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol 1996; 70: 7108-15.
39. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985; 4: 3021-4.
40. Liljestrom P, Lusa S, Huylebroeck D, Garoff H. In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: the small 6, 000-molecular-weight membrane protein modulates virus release. J Virol 1991; 65: 4107-13.
41. Loewy A, Smyth J, von Bonsdorff CH, Liljestrom P, Schlesinger MJ. The 6-kilodalton membrane protein of Semliki Forest virus is involved in the budding process. J Virol 1995; 69: 469-75.
42. Newton K, Meyer JC, Bellamy AR, Taylor JA. Rotavirus nonstructural glycoprotein NSP4 alters plasma membrane permeability in mammalian cells. J Virol 1997; 71: 9458-65.
43. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992; 69: 517-28.
44. Tian P, Estes MK, Hu Y, et al. The rotavirus nonstructural glycoprotein NSP4 mobilizes Ca2+ from the endoplasmic reticulum. J Virol 1995; 69: 5763-72.
45. van Kuppeveld FJ, Hoenderop JG, Smeets RL, et al. Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J 1997; 16: 3519-32.
46. Premkumar A, Wilson L, Ewart GD, Gage PW. Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett 2004; 557: 99-103.
47. Melton JV, Ewart GD, Weir RC, et al. Alphavirus 6K proteins form ion channels. J Biol Chem 2002; 277: 46923-31.
48. Piller SC, Ewart GD, Premkumar A, Cox GB, Gage PW. Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers. Proc Natl Acad Sci USA 1996; 93: 111-5.
49. Schubert U, Ferrer-Montiel AV, Oblatt-Montal M, et al. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett 1996; 398: 12-8.
50. Sunstrom NA, Premkumar LS, Premkumar A, et al. Ion channels formed by NB, an influenza B virus protein. J Membr Biol 1996; 150: 127-32.
51. Gonzalez ME, Carrasco L. Viroporins. FEBS Lett 2003; 552: 28-34.
52. Grice AL, Kerr ID, Sansom MS. Ion channels formed by HIV-1 Vpu: a modelling and simulation study. FEBS Lett 1997; 405: 299-304.
53. Montserret R, Saint N, Vanbelle C, et al. NMR structure and ion channel activity of the p7 protein from hepatitis C virus. J Biol Chem 2010; 285: 31446-61.
54. Patargias G, Zitzmann N, Dwek R, Fischer WB. Protein-protein interactions: modeling the hepatitis C virus ion channel p7. J Med Chem 2006; 49: 648-55.
55. Chew CF, Vijayan R, Chang J, Zitzmann N, Biggin PC. Determination of pore-lining residues in the hepatitis C virus p7 protein. Biophys J 2009; 96: L10-2.
56. Clarke D, Griffin S, Beales L, et al. Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus p7 protein in vitro. J Biol Chem 2006; 281: 37057-68.
57. Luik P, Chew C, Aittoniemi J, et al. The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc Natl Acad Sci USA 2009; 106: 12712-6.
58. Opella SJ, Nevzorov A, Mesleb MF, Marassi FM. Structure determination of membrane proteins by NMR spectroscopy. Biochem Cell Biol 2002; 80: 597-604.
59. Cook GA, Opella SJ. NMR studies of p7 protein from hepatitis C virus. Eur Biophys J 2010; 39: 1097-104.
60. Cook G, Stefer S, Opella SJ. Expression and purification of the membrane protein p7 from HCV. Biopolymers 2010. DOI: DOI: 10.1002/bip.21453 [Epub ahead of print].
61. Cook GA, Zhang H, Park SH, Wang Y, Opella SJ. Comparative NMR studies demonstrate profound differences between two viroporins: p7 of HCV and Vpu of HIV-1. Biochim Biophys Acta 2011; 1808: 554-60.
62. Takeda M, Pekosz A, Shuck K, Pinto LH, Lamb RA. Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 2002; 76: 1391-9.
63. Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 2001; 75: 1252-64.
64. Fischer WB, Sansom MS. Viral ion channels: structure and function. Biochim Biophys Acta 2002; 1561: 27-45.
65. Nomaguchi M, Fujita M, Adachi A. Role of HIV-1 Vpu protein for virus spread and pathogenesis. Microbes Infect 2008; 10: 960-7.
66. Takikawa S, Engle RE, Emerson SU, et al. Functional analyses of GB virus B p13 protein: development of a recombinant GB virus B hepatitis virus with a p7 protein. Proc Natl Acad Sci USA 2006; 103: 3345-50.
67. Bukh J, Apgar CL, Engle R, et al. Experimental infection of chimpanzees with hepatitis C virus of genotype 5a: genetic analysis of the virus and generation of a standardized challenge pool. J Infect Dis 1998; 178: 1193-7.
68. Tuplin A, Wood J, Evans DJ, Patel AH, Simmonds P. Thermodynamic and phylogenetic prediction of RNA secondary structures in the coding region of hepatitis C virus. RNA 2002; 8: 824-41.
69. Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St Petersburg. J Virol 2002; 76: 4034-43.
70. Pietschmann T, Kaul A, Koutsoudakis G, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 2006; 103: 7408-13.
71. Yi M, Ma Y, Yates J, Lemon SM. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol 2007; 81: 629-38.
72. Steinmann E, Penin F, Kallis S, et al. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 2007; 3: e103.
73. Murray CL, Jones CT, Tassello J, Rice CM. Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus. J Virol 2007; 81: 10220-31.
74. Brohm C, Steinmann E, Friesland M, et al. Characterization of determinants important for hepatitis C virus p7 function in morphogenesis by using trans-complementation. J Virol 2009; 83: 11682-93.
75. Gosert R, Egger D, Lohmann V, et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003; 77: 5487-92.
76. Isherwood BJ, Patel AH. Analysis of the processing and transmembrane topology of the E2p7 protein of hepatitis C virus. J Gen Virol 2005; 86 (Part 3): 667-76.
77. Perez-Berna AJ, Guillen J, Moreno MR, et al. Identification of the membrane-active regions of hepatitis C virus p7 protein: biophysical characterization of the loop region. J Biol Chem 2008; 283: 8089-101.
78. Meshkat Z, Audsley M, Beyer C, Gowans EJ, Haqshenas G. Reverse genetic analysis of a putative, influenza virus M2 HXXXW-like motif in the p7 protein of hepatitis C virus. J Viral Hepat 2009; 16: 187-94.
79. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007; 81: 8374-83.
80. Steinmann E, Whitfield T, Kallis S, et al. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 2007; 46: 330-8.
81. StGelais C, Foster TL, Verow M, et al. Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro. J Virol 2009; 83: 7970-81.
82. Ma Y, Anantpadma M, Timpe JM, et al. Hepatitis C Virus NS2 Protein Serves as a Scaffold for Virus Assembly by Interacting with both Structural and Nonstructural Proteins. J Virol 2011; 85: 86-97.
83. Saunier B, Triyatni M, Ulianich L, et al. Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol 2003; 77: 546-59.
84. Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100: 7271-6.
85. Wozniak AL, Griffin S, Rowlands D, et al. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production. PLoS Pathog 2010; 6: e1001087.
86. StGelais C, Tuthill TJ, Clarke DS, et al. Inhibition of hepatitis C virus p7 membrane channels in a liposome-based assay system. Antivir Res 2007; 76: 48-58.
87. Griffin S, StGelais C, Owsianka AM, et al. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel. Hepatology 2008; 48: 1779-90.
88. Jacotot E, Ferri KF, El HC, et al. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med 2001; 193: 509-19.
89. D'Agostino DM, Ranzato L, Arrigoni G, et al. Mitochondrial alterations induced by the p13II protein of human T-cell leukemia virus type 1. Critical role of arginine residues. J Biol Chem 2002; 277: 34424-33.
90. Rahmani Z, Huh KW, Lasher R, Siddiqui A. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. J Virol 2000; 74: 2840-6.
91. Takada S, Shirakata Y, Kaneniwa N, Koike K. Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death. Oncogene 1999; 18: 6965-73.
92. Gibbs JS, Malide D, Hornung F, Bennink JR, Yewdell JW. The influenza A virus PB1-F2 protein targets the inner mitochondrial membrane via a predicted basic amphipathic helix that disrupts mitochondrial function. J Virol 2003; 77: 7214-24.
93. Vance JE. Phospholipid synthesis in a membrane fraction associated with mitochondria. J Biol Chem 1990; 265: 7248-56.
94. Demaurex N, Distelhorst C. Cell biology. Apoptosis - the calcium connection. Science 2003; 300: 65-7.
95. Huang YP, Zhang SL, Cheng J, et al. Screening of genes of proteins interacting with p7 protein of hepatitis C virus from human liver cDNA library by yeast two-hybrid system. World J Gastroenterol 2005; 11: 4709-14.
96. Pavlovic D, Fischer W, Hussey M, et al. Long alkylchain iminosugars block the HCV p7 ion channel. Adv Exp Med Biol 2005; 564: 3-4.
97. Couch RB. Prevention and treatment of influenza. N Engl J Med 2000; 343: 1778-87.
98. Oxford JS, Bossuyt S, Balasingam S, et al. Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. Clin Microbiol Infect 2003; 9: 1-14.
99. Pinto LH, Lamb RA. The M2 proton channels of influenza A and B viruses. J Biol Chem 2006; 281: 8997-9000.
100. Berg T, Kronenberger B, Hinrichsen H, et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology 2003; 37: 1359-67.
101. Griffin S, Trowbridge R, Thommes P, et al. Chimeric GB virus B genomes containing hepatitis C virus p7 are infectious in vivo. J Hepatol 2008; 49: 908-15.
102. Okada A, Miura T, Takeuchi H. Protonation of histidine and histidine-tryptophan interaction in the activation of the M2 ion channel from influenza a virus. Biochemistry 2001; 40: 6053-60.
103. Salom D, Hill BR, Lear JD, DeGrado WF. pH-dependent tetramerization and amantadine binding of the transmembrane helix of M2 from the influenza A virus. Biochemistry 2000; 39: 14160-70.
104. Wang C, Lamb RA, Pinto LH. Activation of the M2 ion channel of influenza virus: a role for the transmembrane domain histidine residue. Biophys J 1995; 69: 1363-71.
105. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32: 630-4.
106. Cozzolongo R, Cuppone R, Manghisi OG. The treatment of chronic hepatitis C not responding to interferon. Curr Pharm Des 2002; 8: 967-75.
107. Deltenre P, Henrion J, Canva V, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol 2004; 41: 462-73.
108. Mangia A, Leandro G, Helbling B, et al. Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol 2004; 40: 478-83.
109. Maynard M, Pradat P, Bailly F, et al. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol 2006; 44: 484-90.
110. Piai G, Rocco P, Tartaglione MT, et al. Triple (interferon, ribavirin, amantadine) versus double (interferon, ribavirin) re-therapy for interferon relapser genotype 1b HCV chronic active hepatitis patients. Hepatol Res 2003; 25: 355-63.
111. Thuluvath PJ, Pande H, Maygers J. Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. Dig Dis Sci 2003; 48: 594-7.
112. Weegink CJ, Sentjens RE, Beld MG, Dijkgraaf MG, Reesink HW. Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study. J Viral Hepat 2003; 10: 174-82.
113. Zilly M, Lingenauber C, Desch S, et al. Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin. Eur J Med Res 2002; 7: 149-54.
114. Chan J, O'Riordan K, Wiley TE. Amantadine's viral kinetics in chronic hepatitis C infection. Dig Dis Sci 2002; 47: 438-42.
115. Mihm U, Grigorian N, Welsch C, et al. Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C. Antivir Ther 2006; 11: 507-19.
116. Luscombe CA, Huang Z, Murray MG, et al. A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antivir Res 2010; 86: 144-53.